Help Desk
860-305-6955
860-305-6955
Phoenix Pharma Labs’ drug candidates deliver potent pain relief with minimal side effects and no addiction risk.
Potent opioids with unique profiles that do not activate Mu or Kappa receptors—free from the serious side effects typically associated with both
| CHARACTERISTIC | MU OPIOIDS | KAPPA OPIOIDS | PPL-103 | PPL-138 |
|---|---|---|---|---|
| Significant Euphoria ("High" Feeling) ( CPP/SA ) |  |  | | |
| Significant Dysphoria ("Bad" Feeling) (CPA) | | | | |
| Lethal Respiratory Depression (Slowed Breathing) at Moderate Dose | | | | |
| Significant Constipation | | | | |
| Withdrawal Symptoms |  | | | |
| Sustains Without Opiate Withdrawal |  |  | | |
| Drowsiness | |  |  | |
Phoenix PharmaLabs has collaborated with scientists at the University of Bath (UK) in the development of a portfolio of 25 Nociceptin compounds including the drug that we now call PPL-138. This compound meets all of our criteria for a potent, safe, non-addicting analgesic for effective treatment of moderate to severe pain. It has demonstrated long duration of action, effective bioavailability in sublingual administration and no development of tolerance after four weeks of chronic administration. Since PPL-138 has such a long duration of action, it has excellent potential for development as a non-addictive treatment for chronic and acute pain.
All technical documentation, findings, and peer-reviewed papers related to PPL-138 – available here in PDF format.
Studies of the drugs have been conducted by prominent scientists at leading institutions including Virginia Commonwealth University (VCU), the University of Michigan, Wake Forest University, SRI International, Torrey Pines Institute for Molecular Studies, ITR Canada, the University of Montreal, University of Bath and Florida Atlantic University (FAU).
Phoenix has a broad IP platform including over two dozen novel analogs. PPL-138 is in IND submission with Phase I trials planned for Q3, 2025. This provides the company with multiple grant opportunities as well as the flexibility to develop different products for different markets (e.g. acute and chronic pain, addiction therapies, PTSD and PTSD/AUD (alcohol use disorder) comorbidity, animal therapies, etc.).
Phoenix Pharma Labs has exclusive license to 25 Nociceptin compounds called PPL-138. In December of 2014 a composition of matter patent covering all of the compounds was filed in the United States and Europe. It was issued in the US in May, 2018 and in Europe in November, 2020. It has been validated in the UK, France, Germany, Spain, Italy, Belgium, Netherlands, and Switzerland.
Formulations, processes and methods of synthesis as well as details concerning additional NCE variants in development are currently protected as trade secrets.
Phoenix Pharma Labs believes its unique compounds potentially offer pain sufferers, whether from acute or chronic conditions, new hope for potent pain relief without addiction or other serious opioid side effects. Additionally, our compounds offer significant potential for development as treatments for cocaine, methamphetamine, and other addictions. We intend to continue to develop new analogs within our portfolio of proprietary molecules.
PPL-138 Studies in Non-Human Primates:
PPL-138 binds to the NOP and mu receptors and then just partially stimulates those receptors. Both mu and NOP produce potent pain relief, but activation of the NOP receptor blocks the release of excessive dopamine, thus preventing the euphoria (and the resulting abuse & addiction).
Mr. Crossman is responsible for the overall management of the Company and the creation, planning and execution of business and financial strategies and corporate development activities, including capital generation.
Crossman is a senior management professional with international and domestic experience as CEO, COO and CFO of enterprises ranging from entrepreneurial start-ups to Fortune 500 level companies. He has a proven track record of successfully commercializing various emerging technologies including manufacturing and industrial systems, computer software, marine bioremediation, nanotechnology and life sciences.
Mr.Crossman has assisted numerous early-stage companies to refine business strategies, commercialize new products, raise capital, license technologies, scale revenues and production, and expand into global markets. As CEO of ISOPur Fluid Technologies, Crossman led the company from product introduction to global growth with expanding applications in multiple vertical markets. Important strategic alliances were developed with Siemens, BHP, Atlas Copco, Hess, Sanwa Shoko and others, creating a platform for continued strong growth.
The value of the founding shareholders’ common stock increased more than tenfold in less than three years under Crossman’s leadership. As CFO of Otis Elevator Company – Asia Pacific Operations, Crossman evaluated, negotiated and developed acquisitions, joint ventures and major capital investments in China, Japan, Korea, India, Southeast Asia, and Australia. Mr. Crossman contributed to profit growth of 20% per year and market share gains of 1% per year in this mature multi-billion dollar operation spanning 23 countries, despite aggressive competition from large Asian conglomerates. The joint ventures that he helped developed in China are among the most profitable operations of United Technologies Corp today. Bill holds a BS degree from the U.S. Merchant Marine Academy at Kings Point and a MBA from the Haas School of Business at the University of California – Berkeley.